I-Ibandronate, isidakamizwa esinamandla esisetshenziselwa ukwelapha i-osteoporosis, isithole ukunakwa ngekhono layo lokuthuthukisa impilo yamathambo. Lo muthi, otholakala njenge-ibandronate 150 mg tablet, unikeza ithemba kulabo abasengozini yokulahlekelwa amathambo kanye nokuphuka, ikakhulukazi abesifazane base-postmenopausal.
Kulo mhlahlandlela ophelele, sizohlola ukusetshenziswa okuhlukahlukene kwe-ibandronate nokuthi ungayithatha kanjani i-ibandronate ngempumelelo.
Umuthi we-Ibandronate, owaziwa nangokuthi i-ibandronate sodium noma i-ibandronic acid, umuthi kadokotela oyingxenye yezidakamizwa ze-bisphosphonate. Yehlisa ukulahleka kwamathambo futhi ikhulise ukuminyana kwamathambo kwamathambo. I-osteoporosis yisifo samathambo lapho amathambo eba mncane futhi abe buthaka, okwandisa amathuba okuphuka.
Inkomba eyinhloko ye-ibandronate ukwelapha nokuvimbela i-osteoporosis kwabesifazane be-postmenopausal. Umuthi ubambezela ngenkuthalo ukuwohloka kwemvelo kwamathambo, ukuqinisa ukwakheka kwamathambo nokunciphisa ingozi yokuphuka.
Odokotela banquma i-ibandronate 150 mg amaphilisi okufanele aphuzwe kanye ngenyanga. Lolu hlobo lwemithi lukhulisa ukuminyana kwamaminerali amathambo (BMD) futhi lwehlisa izehlakalo zokuphuka kwama-vertebral.
Iziguli kufanele ziphuze umuthi we-ibandronate okungenani imizuzu engu-60 ngaphambi kokudla ukudla, isiphuzo (ngaphandle kwamanzi), noma eminye imithi yomlomo ukuze imunce kahle futhi izuze emtholampilo. Kubalulekile ukuthi iziguli zithathe i-calcium kanye i-vitamin D izithasiselo uma ukudla kwazo kunganele.
I-Ibandronate, njenganoma yimuphi umuthi, ingabangela imiphumela emibi. Imiphumela emibi evamile ihlanganisa:
Le miphumela ngokuvamile ayidingi ukunakekelwa kwezokwelapha futhi ingase idambe njengoba umzimba ujwayela umuthi.
Imiphumela emibi kakhulu, nakuba ingajwayelekile kakhulu, ingenzeka. Lokhu kubandakanya:
Iziguli kufanele zazise udokotela wazo mayelana nokungezwani komzimba ne-ibandronate noma eminye imithi. Kufanele badalule yonke imithi eqhubekayo, okuhlanganisa izithasiselo kanye nemikhiqizo yamakhambi. Iziguli kufanele zisebenzise izinyathelo ezithile zokuphepha ngaphambi kokuthatha ibandronate, njenge:
I-Ibandronate, umuthi we-bisphosphonate, ivimbela ukuwohloka kwamathambo futhi yandise ukuminyana kwamathambo. Ibophezela ku-hydroxyapatite emathanjeni futhi ikhishwe ngesikhathi sokuvuselelwa kwamathambo. Ama-osteoclasts, amaseli anesibopho sokubuyisela amathambo, athatha ibandronate ngokusebenzisa i-fluid-phase endocytosis. Ngaphakathi kwama-osteoclasts, ibandronate iphazamisa ama-podosomes, izakhiwo ezivumela ama-osteoclast ukuba anamathele emathanjeni. Le nhlangano ivimbela ukubuyiswa kwamathambo.
I-Ibandronate iphinde ivimbele izingxenye zendlela ye-mevalonate, ebalulekile ekusebenzeni kwamaprotheni. Lokhu kuvinjelwa kuholela ku-apoptosis yama-osteoclasts namanye amaseli. Ngokunciphisa ukuwohloka kwamathambo, i-ibandronate isiza amathambo ukuthi ahlale eqinile futhi anciphise ingozi yokuphuka. Nokho, ilawula i-osteoporosis ngaphandle kokuyelapha, inikeza izinzuzo kuphela inqobo nje uma ithathwa njalo.
Iziguli kufanele njalo zazise udokotela wazo mayelana nemithi yazo eqhubekayo, okuhlanganisa incwadi kadokotela, imithi ethengwa ezitolo, amavithamini, amaminerali, nemikhiqizo yamakhambi. I-Ibandronate ingaxhumana nezidakamizwa eziningi, kufaka phakathi:
Umthamo we-Ibandronate uyahlukahluka futhi uncike esimweni sesiguli. I-Ibandronate itholakala kumaphilisi angu-150 mg noma njengesirinji egcwaliswe ngaphambili engu-1 mg/1mL.
Ngokuvimbela nokwelashwa kwe-postmenopausal osteoporosis, abantu abadala ngokuvamile bathatha umthamo womlomo ongu-2.5 mg nsuku zonke ekuseni noma u-150 mg kanye ngenyanga ngosuku olufanayo. Iziguli kufanele ziphuze ithebhulethi okungenani imizuzu engama-60 ngaphambi kokudla ukudla, isiphuzo, noma eminye imithi ngaphandle kwamanzi.
Ngomthamo wanyanga zonke, uma isiguli sigeja umthamo futhi umthamo olandelayo ohleliwe ungaphezu kwezinsuku eziyisikhombisa, kufanele uwuthathe ngakusasa ekuseni ngemva kokukhumbula. Uma umthamo olandelayo ukude nosuku olu-1 kuya kweziyi-7, kufanele balinde kuze kube yileso sikhathi bese beqa umthamo ogejiwe.
Ekuphathweni komjovo, i-3 mg inikezwa njalo ezinyangeni ezintathu ngemizuzwana eyi-15-30 yokwelashwa kwe-osteoporosis kuphela.
I-Ibandronate ithonya kakhulu impilo yamathambo, inikeza ithemba kulabo ababhekene ne-osteoporosis. Ikhono layo lokunciphisa ukuwohloka kwamathambo nokuqinisa ukuminyana kwamathambo kuyenza ibe ithuluzi elibalulekile lokuvimbela ukuphuka, ikakhulukazi kwabesifazane abangemva kokuya esikhathini. Nakuba kungelona ikhambi, ukusetshenziswa njalo kwe-ibandronate kungathuthukisa kakhulu amandla amathambo kanye nezinga lempilo.
I-Ibandronate iphatha futhi ivimbele i-osteoporosis kwabesifazane be-postmenopausal. Iqinisa amathambo futhi inciphise ingozi yokuphuka.
Imiphumela emibi evamile ihlanganisa ubuhlungu beqolo, ubuhlungu bamalunga noma imisipha, ukungaphatheki kahle kwesisu, nezimpawu ezinjengomkhuhlane. Imiphumela emibi engathi sína, nakuba ingavamile, ingahlanganisa izinkinga zomphimbo, amazinga e-calcium aphansi, nezinkinga zezinso.
Cha, i-ibandronate ijwayele ukuthathwa njengethebhulethi engu-150 mg kanye ngenyanga noma njengomjovo we-3 mg njalo ezinyangeni ezintathu.
Thatha i-ibandronate into yokuqala ekuseni, okungenani imizuzu engu-60 ngaphambi kokudla, isiphuzo, noma eminye imithi. Hlala umile imizuzu engama-60 ngemuva kokuyithatha.
Abantu abanezinkinga zomphimbo, i-calcium ephansi yegazi, izinkinga zezinso ezinzima, noma labo abangakwazi ukuhlala baqonde imizuzu engu-60 kufanele bagweme i-ibandronate.
I-Ibandronate ngokuvamile iphephile uma isetshenziswa njengoba iqondiswe. Kodwa-ke, ukusetshenziswa isikhathi eside kungase kwandise izingozi zokuphuka kwe-atypical kanye nezinkinga zemihlathi.
Ubude besikhathi obufanele buyahlukahluka. Odokotela bangacabanga ukuyeka ngemva kweminyaka engu-3-5 ezigulini ezisengozini encane. Xoxa nodokotela wakho.
I-Ibandronate inyusa ukuminyana kwamaminerali amathambo, ngemijovo ekhombisa imiphumela engcono kakhulu kunamaphilisi. Inciphisa ngempumelelo ingozi yokuphuka kwabesifazane be-postmenopausal abane-osteoporosis.